PDCD1LG2 and neoplasm: These data identified a significant decrease in expression of the immune checkpoint ligand pdcd1lg2 (PD-L2 gene) in Panc47 FAK−/− tumours when compared to FAK-wt tumours (Fig. 1d), supporting our previous observations in murine skin squamous cell carcinoma (SCC) that treatment with the FAK inhibitor BI 853520 could decrease PD-L2 expression on multiple cell types within the TME, contributing towards the improved anti-tumour efficacy of FAK/immunotherapy combinations [24].